Daniel Hunt

Direktor/Vorstandsmitglied bei Antion Biosciences SA

Consumer Services

Health Technology

Profil

Daniel Hunt is currently a Director at Antion Biosciences SA. He completed his undergraduate degree at Stanford University and his graduate degree at the London School of Economics & Political Science.

Aktive Positionen von Daniel Hunt

Unternehmen	Position	Beginn
Antion Biosciences SA Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini.	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Daniel Hunt

Ausbildung von Daniel Hunt

Stanford University	Undergraduate Degree
London School of Economics & Political Science	Graduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Daniel Hunt im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
Antion Biosciences SA Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini.	Health Technology